These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21390517)

  • 1. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
    Inaba K; Arimoto T; Hoya M; Kawana K; Nakagawa S; Kozuma S; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1255-7. PubMed ID: 21390517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
    Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
    Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
    Mark M; Thürlimann B
    Med Oncol; 2012 Sep; 29(3):1477-8. PubMed ID: 21667322
    [No Abstract]   [Full Text] [Related]  

  • 5. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
    Tanguay JS; Ansari J; Buckley L; Fernando I
    Int J Gynecol Cancer; 2009 Apr; 19(3):361-6. PubMed ID: 19407560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.
    Pezzoli M; Bona Galvagno M; Bongioannini G
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25589526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
    Tripodi E; Cormio G; De Giorgi U; Valabrega G; Rubino D; Lepori S; Maltese G; Sabatucci I; Lorusso D
    Int J Gynecol Cancer; 2019 Jan; 29(1):153-157. PubMed ID: 30640698
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
    Meng L; Huang L; Xu Y; Zhang W
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):3-7. PubMed ID: 31377831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.
    Ferrero JM; Weber B; Geay JF; Lepille D; Orfeuvre H; Combe M; Mayer F; Leduc B; Bourgeois H; Paraiso D; Pujade-Lauraine E
    Ann Oncol; 2007 Feb; 18(2):263-8. PubMed ID: 17108151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
    Collins Y; Lele S
    J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
    Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Pendlebury A; DeBernardo R; Rose PG
    Anticancer Drugs; 2017 Aug; 28(7):815-817. PubMed ID: 28542037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
    Monk BJ; Kaye SB; Poveda A; Herzog TJ; Aracil M; Nieto A; Badri N; Parekh TV; Tanović A; Galmarini CM
    Gynecol Oncol; 2014 Jan; 132(1):176-80. PubMed ID: 24211400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
    Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.